Sustained control of viremia following therapeutic immunization in chronically HIV-1-infected individuals

Objective:Viral rebounds inevitably follow interruption of antiretroviral treatment in HIV-1-infected individuals. The randomized ANRS 093 aimed at investigating whether a therapeutic immunization was effective in containing the long-term viral replication following discontinuation of antiretroviral drugs in patients. Methods:Seventy HIV-1-infected patients effectively treated with antiretroviral drugs were randomized to continue treatment alone or in combination with four boosts of ALVAC 1433 and HIV-LIPO-6T vaccines followed by three cycles of subcutaneous interleukin-2. The impact of vaccination on viral replication was assessed by interrupting antiretroviral drugs first at week 40 and thereafter during follow-up until week 100. Antiretroviral drugs were re-initiated according to predefined criteria. Results:The median cumulative time (days) off treatment was greater in the vaccine group (177) than in the control group (89) (P = 0.01). The proportion of time (mean, SE) without antivirals per-patient was 42.8% (5.1) and 26.5% (4.2) in the vaccine and control groups, respectively (P = 0.005). Viremia (median log10 copies/ml), 4 weeks following the first, second and third treatment interruption was higher in control patients (4.81, 4.44, 4.53) in comparison with vaccinated patients (4.48, 4.00, 3.66) (P = 0.42, 0.015 and 0.024, respectively). HIV-specific CD4 and CD8 T-cell responses elicited by the therapeutic immunization strongly correlated with the reduction of the time of antiviral therapy (P = 0.0027 and 0.016, respectively). Conclusion:Our findings provide evidence that therapeutic immunization significantly impacts on HIV-1 replication. This translated into a decrease of up to 40% in the duration of exposure to antiretroviral drugs over 15 months of patients' follow-up.

[1]  C. Rouzioux,et al.  Structured Treatment Interruptions in Primary HIV-1 Infection: The ANRS 100 PRIMSTOP Trial , 2005, Journal of acquired immune deficiency syndromes.

[2]  B. Autran,et al.  Impact of therapeutic immunization on HIV-1 viremia after discontinuation of antiretroviral therapy initiated during acute infection. , 2005, Journal of Infectious Diseases.

[3]  C. Rouzioux,et al.  Immunological and virological efficacy of a therapeutic immunization combined with interleukin-2 in chronically HIV-1 infected patients , 2005, AIDS.

[4]  J. Phair,et al.  Registration of clinical trials. , 2005, AIDS.

[5]  L. Montaner,et al.  Randomized, Controlled Trial of Therapy Interruption in Chronic HIV-1 Infection , 2004, PLoS medicine.

[6]  E. Rosenberg,et al.  Limited Durability of Viral Control following Treated Acute HIV Infection , 2004, PLoS medicine.

[7]  G. Carcelain,et al.  Therapeutic Vaccines for Chronic Infections , 2004, Science.

[8]  Anthony D Kelleher,et al.  Identification of circulating antigen-specific CD4+ T lymphocytes with a CCR5+, cytotoxic phenotype in an HIV-1 long-term nonprogressor and in CMV infection. , 2004, Blood.

[9]  R. Siliciano,et al.  Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4+ T cells , 2003, Nature Medicine.

[10]  A. Telenti,et al.  A prospective trial of structured treatment interruptions in human immunodeficiency virus infection. , 2003, Archives of internal medicine.

[11]  Annapurna Vyakarnam,et al.  Presence of HIV-1 Gag-Specific IFN-γ+IL-2+ and CD28+IL-2+ CD4 T Cell Responses Is Associated with Nonprogression in HIV-1 Infection1 , 2002, The Journal of Immunology.

[12]  H. Günthard,et al.  Stimulation of HIV-specific cellular immunity by structured treatment interruption fails to enhance viral control in chronic HIV infection , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[13]  A. Perelson,et al.  Discontinuation of antiretroviral therapy commenced early during the course of human immunodeficiency virus type 1 infection, with or without adjunctive vaccination. , 2002, The Journal of infectious diseases.

[14]  D. Montefiori,et al.  Structured antiretroviral treatment interruptions in chronically HIV-1-infected subjects , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[15]  J. Lieberman,et al.  Dressed to kill? A review of why antiviral CD8 T lymphocytes fail to prevent progressive immunodeficiency in HIV-1 infection. , 2001, Blood.

[16]  G. M. Ortiz,et al.  The virological and immunological consequences of structured treatment interruptions in chronic HIV-1 infection , 2001, AIDS.

[17]  S. Rowland-Jones,et al.  Skewed maturation of memory HIV-specific CD8 T lymphocytes , 2001, Nature.

[18]  V. Calvez,et al.  Transient Mobilization of Human Immunodeficiency Virus (HIV)-Specific CD4 T-Helper Cells Fails To Control Virus Rebounds during Intermittent Antiretroviral Therapy in Chronic HIV Type 1 Infection , 2001, Journal of Virology.

[19]  M. Mouroux,et al.  HIV RNA and HIV DNA in peripheral blood mononuclear cells are consistent markers for estimating viral load in patients undergoing long-term potent treatment. , 2000, AIDS research and human retroviruses.

[20]  M. Mulligan,et al.  A Significant Number of Human Immunodeficiency Virus Epitope-Specific Cytotoxic T Lymphocytes Detected by Tetramer Binding Do Not Produce Gamma Interferon , 2000, Journal of Virology.

[21]  E. Rosenberg,et al.  Immune control of HIV-1 after early treatment of acute infection , 2000, Nature.

[22]  C. Yoder,et al.  Metabolic and anthropometric consequences of interruption of highly active antiretroviral therapy , 2000, AIDS.

[23]  G. M. Ortiz,et al.  Enhancement of human immunodeficiency virus type 1-specific CD4 and CD8 T cell responses in chronically infected persons after temporary treatment interruption. , 2000, The Journal of infectious diseases.

[24]  Douglas D. Richman,et al.  HIV-Specific Cd8+ T Cells Produce Antiviral Cytokines but Are Impaired in Cytolytic Function , 2000, The Journal of experimental medicine.

[25]  R H Lyles,et al.  Natural history of human immunodeficiency virus type 1 viremia after seroconversion and proximal to AIDS in a large cohort of homosexual men. Multicenter AIDS Cohort Study. , 2000, The Journal of infectious diseases.

[26]  R. Lempicki,et al.  HIV-1 and T cell dynamics after interruption of highly active antiretroviral therapy (HAART) in patients with a history of sustained viral suppression. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[27]  E. Rosenberg,et al.  Association between Virus-Specific Cytotoxic T-Lymphocyte and Helper Responses in Human Immunodeficiency Virus Type 1 Infection , 1999, Journal of Virology.

[28]  P. Kissinger,et al.  Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. , 1998, The New England journal of medicine.

[29]  M. Lederman,et al.  Recovery of the immune system with antiretroviral therapy: the end of opportunism? , 1998, JAMA.

[30]  M A Nowak,et al.  Quantitation of HIV-1-specific cytotoxic T lymphocytes and plasma load of viral RNA. , 1998, Science.

[31]  G. Satten,et al.  Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. , 1998, The New England journal of medicine.

[32]  M A Nowak,et al.  Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[33]  E. Rosenberg,et al.  Vigorous HIV-1-specific CD4+ T cell responses associated with control of viremia. , 1997, Science.

[34]  D. Richman,et al.  Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. , 1997, Science.

[35]  R Brookmeyer,et al.  Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. , 1997, Science.

[36]  D. Ho,et al.  Virologic and immunologic characterization of long-term survivors of human immunodeficiency virus type 1 infection. , 1995, The New England journal of medicine.

[37]  G. Shaw,et al.  Virus-specific CD8+ cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection , 1994, Journal of virology.

[38]  D. Ho,et al.  Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome , 1994, Journal of virology.

[39]  G. M. Ortiz.  Structured treatment interruptions in chronically HIV-1 infected subjects , 2001 .

[40]  J. Margolick,et al.  Natural History of Human Immunodeficiency Virus Type 1 Viremia after Seroconversion and Proximal to AIDS in a Large Cohort of Homosexual Men , 2022 .